Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 15 March, 2005

XTL Biopharm Ltd

Directorate Change

XTL Biopharmaceuticals Ltd
15 March 2005

                           XTL Biopharmaceuticals Ltd

                                  Board Change

Rehovot,Israel 15 March 2005 - XTL Biopharmaceuticals Ltd ('XTLbio') (LSE: XTL) today
announces the appointment of Michael Weiss as Interim Non-Executive Chairman
with immediate effect. Mr. Weiss became a Non-Executive Director of XTLbio in
November 2004 and is also Chairman and CEO of New York-based Keryx
Biopharmaceuticals, Inc.

'With the new board in place following the successful shareholder requisition, I
felt it was an appropriate time for me to take a leadership role in XTLbio'
stated Mr. Weiss, who continued, 'with the new board members we have added
substantial expertise in research and development as well as regulatory affairs
and with particular expertise in hepatitis C. We look forward to transitioning
the Company into a disciplined and focused biotechnology company dedicated to
creating shareholder value. Our early efforts will also focus on commencing the
Nasdaq listing process and identifying a US-based Chief Executive to lead the

Jonathan Burgin, CFO
Tel: +972 8 930 4440

Financial Dynamics
Julia Phillips / Sarah MacLeod
Tel: +44 (0) 20 7831 3113

Notes to Editors
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeXTM product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
Established in 1993, XTLbio became a public company in 2000 and its shares are
listed on the Official List of the UK Listing Authority and are traded on the
London Stock Exchange under the symbol XTL.

                      This information is provided by RNS
            The company news service from the London Stock Exchange